About Michael Davidson
Michael H. Davidson, MD, co-founded SonoThera and is its executive chairman. He is also CEO of NewAmsterdam Pharma and directs the Lipid Clinic at the University of Chicago, where he is a professor of medicine.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Michael Davidson in the role, so the role may have started earlier or lasted longer.
SonoThera, Inc. Current
Co-founder and Executive Chairman
2022 – Present · South San Francisco, CA
SonoThera develops nonviral genetic medicines that use ultrasound and imaging microbubbles to deliver DNA and RNA into chosen organs, starting with Duchenne muscular dystrophy.
NV
NewAmsterdam Pharma Co N.V. Current
Chief Executive Officer and director
2020 – Present · Public company (NAMS)
UC
University of Chicago Current
Professor of Medicine and Director of the Lipid Clinic
BI
TI
Tenax Therapeutics, Inc.
Director
2021 – 2026 · Public company (TENX)
SP
Silence Therapeutics plc
Director
2025 · Public company (SLN)
LI
Lisata Therapeutics, Inc.
Director
2020 – 2022 · Public company (LSTA)
OI
Omthera Pharmaceuticals, Inc.
Executive VP & CMO
Founder (From 2008)
2008 – 2013 · Public company (OMTH)
NA
National Lipid Association
President
2010 – 2011
CT
Corvidia Therapeutics
CEO and CSO
CR
Chicago Center for Clinical Research
Founder
NB
NanoPhoria Bioscience
Board member
CB
Caladrius BioScience
Board member
Key Colleagues at Startups
The people Michael Davidson works with at each company, as listed on that company's latest Form D.
SonoThera, Inc. · Form D, Jun 30, 2026
SF
Steven Feinstein
Co-founder & Chief Scientific Officer
KG
Kenneth Greenberg
Co-founder, President & CEO, director
RJ
Rajul Jain
Director
SG
Steven Gillis
Director
Rakhshita Dhar
Director
CZ
Carolyne Zimmermann
Chief Business Officer
BH
Brian Halak
Director